About 90% of patients in Spain survive thyroid cancer. AECAT says care must also track lasting symptoms and the ability to return to ordinary life.
In 2026, Spain is expected to record 6,678 new thyroid cancer diagnoses, according to estimates cited by the Asociación Española de Cáncer de Tiroides, or AECAT. The association says treatment results should track what happens after the operating room, including physical wellbeing and emotional wellbeing.
Women will account for most cases. Figures from SEOM and REDECAN, cited by AECAT, put the total at 4.941 diagnoses among women compared with 1.738 among men. Thyroid cancer represents 13.4% of cancers diagnosed between the ages of 20 and 39. REDECAN projects 301 884 new cancer diagnoses of all types in Spain during 2026, including about 16 432 cases among people younger than 45.
An analysis of 15 Spanish cancer registries found that thyroid cancer incidence among men aged 20–49 rose by approximately 4% annually between 1993 and 2018.
The association has presented a ten-point programme through its campaign ‘Avances que cambian vidas’. Its central complaint is practical: scientific and technological progress has limited value when patients still face avoidable complications, weak follow-up or inadequate support after initial treatment.
The operation can shape the rest of a patient’s life.
Most patients undergo partial or total thyroidectomy. Complete removal of the gland requires lifelong hormone replacement with daily levothyroxine and regular TSH monitoring. After cancer treatment, the target TSH level may initially be set lower and later reconsidered when follow-up remains favourable. Surgery can also affect structures that require continued monitoring. AECAT therefore wants the type of operation selected carefully, with evaluated technologies and protocols protecting the parathyroid glands and other essential structures.
Modern high-resolution ultrasound, fine-needle aspiration, molecular testing and pathology can help assess how aggressive a thyroid nodule is. Those tools can also distinguish patients who may need surgery from those for whom surveillance or another approach may be appropriate. That supports AECAT’s argument for individual decisions on surgical extent rather than automatic total thyroidectomy. The registry evidence among younger men adds weight because treatment consequences can last for decades.
Chronic hypoparathyroidism can affect more than calcium levels: disrupted calcium–phosphate balance may involve the kidneys, bones and nervous system, with possible neuromuscular, cognitive and renal consequences. Long-term follow-up should therefore consider phosphate, magnesium, kidney function, symptoms and quality of life as well as calcium.
That focus matters when symptoms continue after surgery. Hypoparathyroidism can increase physical and cognitive burdens while adding to treatment needs. AECAT says complications should be prevented where possible, detected early and treated properly. Patients with continuing difficulties should have access to specialised teams.
Published clinical materials describe anxiety and depression among the possible effects. They also point to reduced physical activity, so-called brain fog and difficulty remaining in work. About 80% of people with chronic hypoparathyroidism are women, and roughly one-third may be unable to work. A return to ordinary routines is therefore a clinical outcome, not a social extra.
AECAT’s proposal reaches beyond the operating theatre. It calls for coordinated care involving surgery and endocrinology, with oncology, nuclear medicine, primary care, nursing, mental health services and other specialties added when necessary. The association wants care to continue after the first treatment phase because some needs remain for months or years.
Follow-up should include endocrine review and assessment of calcium–phosphate balance. It should also cover kidney function, hormone adjustment and cognitive or psychological symptoms. The practical test is whether the system catches long-term complications before they harden into a patient’s daily routine.
Clear information is another central demand. Patients should receive understandable explanations at each stage of treatment so they can weigh alternatives and take part in decisions about their health. Psychological care should begin at diagnosis and remain available through follow-up rather than being treated as an optional extra.
The need is visible even when no detectable disease remains. Fear of recurrence and fatigue can obstruct a return to normal routines. So can difficulty maintaining hormonal balance and chronic after-effects. AECAT wants those problems recorded alongside cancer control.
Access to innovation sits within a wider European debate over how quickly new treatments reach patients. For thyroid cancer, AECAT points to molecular tests and targeted therapies, while also seeking access to new surgical technologies and future treatments. Its position is that clinical need should guide access rather than severe deterioration.
Research remains part of the programme. AECAT is asking for continued work on disease biomarkers and prognostic factors. It also wants patients’ experience to influence research priorities, care pathways and the way results are assessed.
Published clinical materials also describe wider consequences of chronic hypoparathyroidism. Disrupted calcium and phosphate balance can affect bones, kidneys and the nervous system, with neuromuscular symptoms, renal complications, cognitive problems and tissue calcification reported among the possible effects. Follow-up therefore needs more than a calcium test. It must include phosphate, magnesium, kidney function, symptoms and quality of life.
For Spain’s 2026 thyroid cancer estimates, REDECAN data put new diagnoses among men at 1.738. The registry analysis found that incidence among men aged 20 to 49 rose by approximately 4% annually between 1993 and 2018.
